Cargando…

PB2068: RETROSPECTIVE ANALYSIS OF HAIRY CELL LEUKEMIA (HCL) PATIENTS (PTS) TREATED WITH DIFFERENT MODALITIES AS FIRST LINE: REAL-LIFE EXPERIENCE OVER 20 YEARS IN KUWAIT.

Detalles Bibliográficos
Autores principales:	Alhuraiji, A., Ram, M., Kunhikrishnan, A., Alshemmari, S., Hamadah, A., Shah, A. R., Khadadah, F., Pandita, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429531/ http://dx.doi.org/10.1097/01.HS9.0000851104.44453.64

Ejemplares similares

PB2068: RARITY MATTERS! THE EXPERIENCE IN OUR ADULT HEMATOLOGY SERVICE.
por: Perolla, Adela, et al.
Publicado: (2023)

Evaluation of the CLL-IPI and IPS-E Prognostic Indices in a Young Middle Eastern Population with Chronic Lymphocytic Leukemia: A Retrospective Analysis at the Kuwait Cancer Control Center
por: Alshemmari, Salem H., et al.
Publicado: (2023)

PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES
por: Shadman, M., et al.
Publicado: (2022)

PB1868: EXPERIENCE IN THE TREATMENT OF HAIRY CELL LEUKEMIA IN KAZAKHSTAN.
por: Kemelbekov, N., et al.
Publicado: (2022)

Epidemiology of de novo Acute Myeloid Leukemia in Kuwait per the 2016 WHO Classification
por: Alshemmari, Salem H., et al.
Publicado: (2022)

PB1867: PURINE ANALOGS ON HAIRY CELL LEUKAEMIA TREATMENT
por: Gomes, G., et al.
Publicado: (2022)

PB2069: A CASE OF HAIRY CELL LEUKEMIA PRESENTED AS HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
por: Almeida, C., et al.
Publicado: (2022)

PB1885: THE ROLE OF PET CT IN HAIRY CELL LEUKEMIA
por: itchaki, G., et al.
Publicado: (2022)

PB2282: MEK-KINASE INHIBITOR (TRAMETINIB) AS A TREATMENT OPTION FOR HAIRY CELL LEUKEMIA
por: Smirnova, Svetlana, et al.
Publicado: (2023)

The Cost of Asthma in Kuwait
por: Khadadah, Mousa
Publicado: (2012)

Immunophenotypic Analysis of Hairy Cell Leukemia (HCL) and Hairy Cell Leukemia-like (HCL-like) Disorders
por: Maitre, Elsa, et al.
Publicado: (2022)

PB2003: REAL-WORLD TREATMENT PATTERNS OF PATIENTS (PTS) WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)
por: Komrokji, Rami S., et al.
Publicado: (2023)

PB2283: IN THE ERA OF IMMUNOPHENOTYPING AND MOLECULAR DIAGNOSTICS DOES MORPHOLOGY PLAY AN ESSENTIAL ROLE IN DIFFERENTIATING HAIRY CELL LEUKEMIA FROM ITS MIMICS?
por: Balasubramanian, Priyavadhana, et al.
Publicado: (2023)

PB2110: PREDICTORS OF FRONTLINE (FL) DOUBLET OR TRIPLET REGIMEN USE AMONG TRANSPLANT-INELIGIBLE (TIE) PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) USING A MACHINE LEARNING APPROACH
por: Pianko, Matthew J., et al.
Publicado: (2023)

PB2296: ROBUST BRUTON’S TYROSINE KINASE (BTK) DEGRADATION WITH NX-5948, AN ORAL BTK DEGRADER, IN A FIRST-IN-HUMAN PHASE 1A TRIAL IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES
por: Linton, Kim, et al.
Publicado: (2023)

PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
por: Palandri, Francesca, et al.
Publicado: (2023)

Updates in hairy cell leukemia (HCL) and variant-type HCL (HCL-V): rationale for targeted treatments with a focus on ibrutinib
por: Paillassa, Jérôme, et al.
Publicado: (2022)

Protein profiling by reverse phase protein array (RPPA) in classical hairy cell leukemia (HCL) and HCL‐variant
por: Hoff, Fieke W., et al.
Publicado: (2022)

PB1900: COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS
por: Galdean, S.-M., et al.
Publicado: (2022)

PB2351: ANXIETY AT THE HEMATOLOGIST
por: Trojan, S., et al.
Publicado: (2022)

CD2068 potentially mediates multidrug efflux in Clostridium difficile
por: Ngernsombat, Chawalit, et al.
Publicado: (2017)

PB1827: ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
por: Marques, I., et al.
Publicado: (2022)

PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

PB2258: MANAGEMENT OF FEBRILE NEUTROPENIA IN LEUKEMIC PATIENTS: A MONOCENTRIC STUDY
por: Boufrikha, W., et al.
Publicado: (2022)

PB2363: REPORTING LANGUAGE IN HAEMATOLOGICAL MALIGNANCIES
por: Watt, S., et al.
Publicado: (2022)

PB1781: THERAPEUTIC POTENTIAL OF DNA DAMAGE RESPONSE IN ACUTE MYELOBLASTIC LEUKEMIA
por: Lapa, B., et al.
Publicado: (2022)

PB2282: HERPESVIRUSES REPLICATION DURING COVID-19 IN NON-HODGKIN’S LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

PB2049: MEXICAN REGISTRY OF MYELOPROLIFERATIVE NEOPLASMS. INITIAL REPORT
por: De La Peña Celaya, J. A., et al.
Publicado: (2022)

PB1939: CLINICAL AND GENETIC CHARACTERISTICS OF PATIENTS WITH GAUCHER DISEASE: A SINGLE CENTER EXPERIENCE
por: Elsayed, S., et al.
Publicado: (2022)

PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS
por: Ramos, M. J., et al.
Publicado: (2022)

PB2327: BONE MARROW STUDY IN THROMBOPENIA
por: López De Ugarriza, P., et al.
Publicado: (2022)

PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

PB1782: ZINC IN THE MODULATION OF THE ANTIPROLIFERATIVE AND CYTOTOXIC EFFECTS OF OLAPARIB IN ACUTE MYELOID LEUKEMIA
por: Costa, M. I., et al.
Publicado: (2022)

PB2301: PEDIATRIC IMMUNE THROMBOCYTOPENIA; A GLANCE AT PATIENTS AND CURRENT THERAPEUTIC CHALLENGES
por: Al-Jadiry, M., et al.
Publicado: (2022)

PB1861: ACALABRUTINIB IN THE TREATMENT OF RICHTER SYNDROME
por: Byalik, T., et al.
Publicado: (2022)

PB2165: BIOINFORMATIC TOOL FOR IMMUNOMODULATING THE ONCOGENIC TRANSCRIPTOME OF ABC-DLBCLS
por: Rodríguez, M., et al.
Publicado: (2022)

PB2330: CORONARY ARTERY DISEASE (CAD) AND XBAI GENE POLYMORPHISM (RS693) IN EGYPTIAN PATIENTS
por: Almenshawy, A., et al.
Publicado: (2022)

Reactive lesions of the oral cavity: A retrospective study on 2068 cases
por: Naderi, Noushin Jalayer, et al.
Publicado: (2012)

PB2047: MOLECULAR DIAGNOSIS OF CONGENITAL ERYTHROCYTOSIS IN A SINGLE HOSPITAL CENTER.
por: Castilla Garcia, L., et al.
Publicado: (2022)

PB2091: INFLUENCE OF HISTOLOGICAL GRADE IN CLINICAL CHARACTERISTICS AND LONG-TERM OUTCOME OF FOLICULAR LYMPHOMA
por: Zamanillo, I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_30mj5msp8iimvqmt436trov5ne